Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.

She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on 

Articles

The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) whether or not they were receiving background antifibrotic therapy.

Nerandomilast Slows Lung Function Decline in Patients With IPF

Research presented at the American Thoracic Society (ATS) 2025 International Conference used FDA-approved tools to see how sleep can impact other parts of recovery for patients in the intensive care unit (ICU).

Sleep Patterns, Predictors, and Pharmacologic Interventions in the ICU

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

The FDA previously approved Jivi in 2018 to treat adults aged 12 years and older with hemophilia A.

FDA Approves Jivi for Pediatric Patients Aged 7 to 12 Years With Hemophilia A

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Over 500,000 US patients hospitalized with nonsevere COVID-19 saw no clinically significant benefit and potential harm associated with routine early antibiotic treatment, supporting antibiotic stewardship to limit unnecessary use.

The Argument Against Routine Antibiotics for Patients With Nonsevere COVID-19

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1.125rem

Senior lecturer, University of Western Australia

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in evaluating treatment effects in chronic obstructive pulmonary disease (COPD). 

Improving COPD Trial Efficiency Using the Win Ratio: Sanjay Ramakrishnan, MD